WWW.6-DOMAINS.COM IS NOT INTENDED FOR US, UK OR IRELAND AUDIENCES

Oligoarticular psoriatic arthritis

Professor Pascal Richette and Dr Frank Behrens discuss their experience with oligoarticular psoriatic arthritis patients and the unmet need in this phenotype.

Play button

Oligoarticular psoriatic arthritis affects four or less joints and is usually asymmetrical.63 It is the most common type of psoriatic arthritis at presentation, with around 50% (and up to ~70%) of patients initially presenting with oligoarticular disease.46,64-65

Polyarticular psoriatic arthritis affects five or more joints65 and is more likely to cause erosive disease than oligoarthritis (see Figure 8).65,66

<p>Fig. 8 Percentage of patients with erosive disease <sup>65,66</sup></p>

Fig. 8 Percentage of patients with erosive disease 65,66

Tap to zoom zoom

Despite oligoarthritis affecting fewer joints and being a less destructive form of psoriatic arthritis, in a study comparing disease burden, patients with oligoarticular psoriatic arthritis report a generally greater disease burden than those with polyarticular psoriatic arthritis (see Figure 9).67

Patients with oligoarticular psoriatic arthritis and involvement of one or more of the core domains of psoriatic arthritis (see Figure 10) require a treatment that demonstrates efficacy in the broad manifestations of psoriatic arthritis.51,64,67

Download the consultation tool
<p>Fig. 9 Disease burden of polyarthritis compared to oligoarthritis</p>

Fig. 9 Disease burden of polyarthritis compared to oligoarthritis

Tap to zoom zoom
<p>Fig. 10 Presence of core domains psoriatic arthritis</p>

Fig. 10 Presence of core domains psoriatic arthritis

Tap to zoom zoom

References

1. Kavanaugh A, et al. Rheumatol Ther 2016;3:91–102
2. Kyriakou A, et al. Sci World J 2014; Article ID 508178;
3. Lee E, et al. J Exp Med 2004;199:125–30;
4. Lowes M, et al. J Invest Dermatol 2008;128:1207–11
5. Yao Y, et al. PLoS One 2008;3:e2737
6. Taylan A, et al. Rheumatol Int 2012;32:2511
7. Limon-Camacho L, et al. J Rheumatol 2012;39:830–5.
8. Van Kuijk A and Tak P. Curr Rheumatol Rep 2011;13:353–9
9. Ritchlin C, et al. J Rheumatol 1998;25:1544–52
10. Menon B, et al. Arthritis Rheumatol 2014;66:1272–81
11. Celis R, et al. Arthritis Res Ther 2012;14:R93
12. Spadaro A, et al. Ann Rheum Dis 2002;6:174–6
13. Molteni S and Reali E. Psoriasis: Targets and Therapy 2012;2:55–66
14. Siegel E, et al. Curr Opin Rheumatol 2015;27:111–7
15. Lories R, et al. Nat Med 2012;18:1018–9
16. Ebihara S, et al. Autoimmunity 2015;29:1–8
17. Ruutu M, et al. Arthritis Rheum 2012;64;2211–22
18. Sherlock J, et al. Nat Med 2012;18:1069–77
19. Yamamoto M, et al. J Invest Dermatol 2015;135:445–53
20. Reinhardt A, et al. Arthritis Rheumatol 2016;68:2476–86
21. Coates LC, et al. Lancet 2015;386:2489–98.
22. Mease PJ, et al. Drugs 2014;74:423–41.
23. Schafer P. Biochem Pharmacol 2012;83:1583–90.
24. Van Kuijk A and Tak P. Curr Rheumatol Rep 2011;13:353–9
25. Ritchlin C, et al. J Rheumatol 1998;25:1544–52

26. Menon B, et al. Arthritis Rheumatol 2014;66:1272–81
27. Celis R, et al. Arthritis Res Ther 2012;14:R93
28. Spadaro A, et al. Ann Rheum Dis 2002;6:174–6
29. Molteni S and Reali E. Psoriasis: Targets and Therapy 2012;2:55–66
30. Siegel E, et al. Curr Opin Rheumatol 2015;27:111–7
31. Lories R, et al. Nat Med 2012;18:1018–9
32. Ebihara S, et al. Autoimmunity 2015;29:1–8
33. Ruutu M, et al. Arthritis Rheum 2012;64;2211–22
34. Sherlock J, et al. Nat Med 2012;18:1069–77
35. Yamamoto M, et al. J Invest Dermatol 2015;135:445–53.
36. Reinhardt A, et al. Arthritis Rheumatol 2016;68:2476–86
37. Taylan A, et al. Rheumatol Int 2012;32:2511
38. Limon-Camacho L,et al. J Rheumatol 2012;39:830–5.
39. Lee E, et al. J Exp Med 2004;199:125–30
40. Lowes M, et al. J Invest Dermatol 2008;128:1207–11
41. Yao Y, et al. PLoS One 2008;3:e2737
42. Kyriakou A, et al. Sci World J 2014;Article ID 508178.
43. Gottlieb A, et al. J Am Acad Dermatol 2008;58:851–64.
44. Scutellari P, et al. Eur J Radiol 1998;27(suppl 1):S31–38.
45. Coates LC, et al. Arthritis Rheumatol 2016;68:1060–71.
46. Moll JMH and Wright V. Semin Arthritis Rheum 1973;3:55–78.
47. Helliwell PS. Clin Rheum 2015;33:S44-47
48. McGonagle D, et al. Lancet 1998;352:1137–40.
49. McGonagle D & McDermott MF. PLoS Med 2006;3:e29.

50. Schett G, et al. Nat Rev Rheumatol 2017;13:731–41.
51. Ritchlin CT, et al. N Engl J Med 2017;376:957–70
52. Ravindran J, et al. Arthritis Care Res 2010;62:86–91.
53. Gladman DD, et al. Arthritis Rheum 2007;56:476–88.
54. Kavanaugh A, et al. Arthritis Rheum 2012;64:2504–17.
55. Kavanaugh A, et al. Ann Rheum Dis 2014;73:1020–6
56. van der Heijde D, et al. Arthritis Rheum 2016;68:1914–21
57. Strand V & Sharp JT. Arthritis Rheum 2003;48:21–34.
58. van der Heijde, et al. Ann Rheum Dis 2005; 64(Suppl II):ii61–4.
59. Husted JA, et al. Arthritis Care Res (Hoboken) 2011;63:1729–35
60. Husted JA, et al. J Rheumatol 2013;40:1349–56.
61. Edson-Heredia E, et al. J Eur Acad Dermatol Venereol 2015;29:955–63.
62. Ogdie A, et al. J Rheumatol 2014;41:2315–22.
63. Ogdie A, et al. J Invest Dermatol 2017 [Epub]
64. Coates LC et al. Arthritis Rheum. 2013;65:1504–9.
65. Nossent JC and Gran JT. Scand J Rheumatol 2009;38:251–5
66. Lindqvist URC et al. J Rheum 2008;35:668–73.
67. Huscher D, et al. ACR 2015: Abstract 679.
68. Coates LC, et al. Arthritis Rheumatol 2016;68:1060–71.
69. Veale DJ & Fearon U. RMD Open 2015;1:e000025.
70. Wilsdon TD, et al. Cochrane Database Syst Rev 2017, Art. No.: CD012722.
71. Kingsley GH, et al. Rheumatology 2012;51:1368–77.
72. van de Kerkhof PCM, et al. J Eur Acad Dermatol Venereol 2015;29:2002–10.
73. Lebwohl MD, et al. J Am Acad Derm 2014;70:871–81.
74. van Mens LJJ, et al. Arthritis Res Ther 2017;19:226.

celgene

© Celgene Corporation 2018. All rights reserved
Six Domains Programme was developed by Celgene

logo white

We use cookies to improve the website and your navigation experience based on our Terms of Use and Privacy Policy. To accept cookies continue to browse the site or click the button. For information on how we use cookies and how to disable them, please visit our Cookies Policy.

OK